LINC01194 and Familial prostate cancer: The potential implication of these data is that treatment with STEAP1-BBζ CAR T cell therapy and resultant loss of STEAP1 tumor antigen expression in prostate cancer may result in further immunotherapy resistance through impaired antigen processing and presentation.